A review of current phase III clinical trials of plaque psoriasis: Underrepresentation of non-white subjects and need for reform.
A review of current phase III clinical trials of plaque psoriasis: Underrepresentation of non-white subjects and need for reform.
Br J Dermatol. 2020 Aug 07;:
Authors: Reddy VD, Myers BA, Chan SY, Thibodeaux QG, Brownstone ND, Bhutani T, Liao W, Lester JC, Koo JY
Abstract
Plaque psoriasis is a chronic inflammatory skin condition that affects an estimated 0.91% to 8.5% of the global population.1 The prevalence of psoriasis varies based on ethnoracial and geographic distribution. In the United States, psoriasis affects approximately 3.6% of Caucasians (non-Hispanic white), 1.9% of African Americans (non-Hispanic black), and 1.6% of Hispanic-identifying adults.2 Population-based studies in East and Southeast Asia have estimated a prevalence ranging from 0.05 to 0.47%.3.
PMID: 32767747 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Reddy VD, Myers BA, Chan SY, Thibodeaux QG, Brownstone ND, Bhutani T, Liao W, Lester JC, Koo JY Tags: Br J Dermatol Source Type: research
More News: African Health | Clinical Trials | Dermatology | Psoriasis | Skin | Study | UK Health | USA Health